InSilico Medicine Cayman TopCo
HKEX:3696
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
InSilico Medicine Cayman TopCo
HKEX:3696
|
HK |
|
FDM Group (Holdings) PLC
OTC:FDDMF
|
UK |
|
Burkhalter Holding AG
F:BKMA
|
CH |
|
NCC Group PLC
OTC:NCCGF
|
UK |
|
A
|
AIA Group Ltd
SWB:7A2
|
HK |
|
B
|
Beigene Ltd
SWB:49B
|
KY |
|
C
|
Canada Goose Holdings Inc
NYSE:GOOS
|
CA |
|
C
|
Croda International PLC
DUS:6CMB
|
UK |
|
Medical Developments International Ltd
ASX:MVP
|
AU |
|
G
|
Gladstone Commercial Corp
F:GLE
|
US |
|
D
|
Dr Reddy's Laboratories Ltd
BSE:500124
|
IN |
|
Flight Centre Travel Group Ltd
ASX:FLT
|
AU |
|
Compagnie du Cambodge SA
LSE:0I76
|
FR |
|
L
|
Lenovo Group Ltd
SWB:LHL
|
CN |
|
C
|
Carnival PLC
F:POH3
|
UK |
Wall St Price Targets
Price Targets Summary
InSilico Medicine Cayman TopCo
According to Wall Street analysts, the average 1-year price target for InSilico Medicine Cayman TopCo is 76.91 HKD with a low forecast of 74.74 HKD and a high forecast of 80.64 HKD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is InSilico Medicine Cayman TopCo's stock price target?
Price Target
76.91
HKD
According to Wall Street analysts, the average 1-year price target for InSilico Medicine Cayman TopCo is 76.91 HKD with a low forecast of 74.74 HKD and a high forecast of 80.64 HKD.
What is the Revenue forecast for InSilico Medicine Cayman TopCo?
Projected CAGR
65%
Over the last 1 year, the compound annual growth rate for Revenue has been -34%. The projected CAGR for the next 3 years is 65%.
